Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment.
about
The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease.Repression of choroidal neovascularization through actin cytoskeleton pathways by microRNA-24.Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy.Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degenerationA delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration.Blood expression levels of chemokine receptor CCR3 and chemokine CCL11 in age-related macular degeneration: a case-control study.Foveal morphology affects self-perceived visual function and treatment response in neovascular age-related macular degeneration: a cohort study.Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcomeOptical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based AnalysisLet-7 contributes to diabetic retinopathy but represses pathological ocular angiogenesis.In patients with neovascular age-related macular degeneration, physical activity may influence C-reactive protein levels.Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.Gene therapy for age-related macular degeneration.Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.Altered activation state of circulating neutrophils in patients with neovascular age-related macular degeneration.Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration.Strand and Cell Type-specific Function of microRNA-126 in AngiogenesisInduced pluripotent stem cell-based therapy for age-related macular degeneration.Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.Cataract surgery in patients with neovascular age-related macular degeneration.Long-Term Outcomes in Patients with Neovascular Age-Related Macular Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab Injections.Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline.
P2860
Q27324293-9329F5D9-4746-4498-BCE6-7420D5797053Q30571075-C46100D1-DEE0-42E6-82D3-EB560D7FFE41Q33808827-8908EA8D-E0DA-4AE9-B9D1-AAD317621BDCQ34092569-3106E23B-EB83-410A-8CEE-580FFC5E6163Q34815427-6116F44D-A435-4893-849C-67FE6A29334DQ35103889-5CED7DCF-7BA3-4F69-8CF0-89DDA46B24FDQ35117715-8C7F7B9A-C31B-4FBF-8FC2-AF075BCC91E3Q35503206-52918ABF-0739-4827-84A0-3282638EC871Q35996271-FFB0C5E4-8D1B-4C23-8E58-DE6D154F5F88Q36393604-8BC544CB-2177-4257-9E5D-26353AE3022AQ37391131-1AD022C7-726B-4781-98FE-034C2F9471BCQ37702363-603DDBC3-0FCC-4359-8DF9-8E23CEFE2274Q38094076-2F4FA7B5-B25B-4D8A-8C8B-0ED9231B3B0FQ38654588-DD879A50-429E-488F-AF9B-5E35DF3EB970Q38706624-969424FB-CAA0-4DFF-A6AD-92FE39978C4AQ41150037-9FC7FE9B-A7E1-47FD-B771-F879BD53AA0FQ41464400-2DC53B5A-640A-4F63-90FF-3DA6A582B5DCQ41653973-5B0605AB-D810-415C-BABD-3590D086D151Q48218214-95A15A68-A64A-4404-BE8C-B183975E7245Q48520571-15C206FE-19AF-4B43-9370-8E6E283CBCCCQ51723541-F01FE65C-8292-4ED9-8923-DCFEA648569CQ52677250-81BC3AD2-9269-475D-9ADD-D61C00083A65Q54942391-F23B60AF-7CD5-46E6-A369-FCB64D18EB80
P2860
Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Four-year treatment results of ...... discontinuation of treatment.
@en
type
label
Four-year treatment results of ...... discontinuation of treatment.
@en
prefLabel
Four-year treatment results of ...... discontinuation of treatment.
@en
P2093
P1476
Four-year treatment results of ...... discontinuation of treatment.
@en
P2093
Henrik Kemp
Mads Krüger Falk
Torben Lykke Sørensen
P304
P356
10.1016/J.AJO.2012.06.031
P407
P577
2012-09-27T00:00:00Z